JGC
URGN icon

J. Goldman & Co’s UroGen Pharma URGN Stock Holding History

J. Goldman & Co’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$899K Sell
50,000
-34,000
-40% -$682K 0.03% 437
2025
Q4 		$1.97M Buy
+84,000
New +$1.82M 0.05% 318

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

J. Goldman & Co's URGN Position: Q1 2026 in Review

J. Goldman & Co increased its UroGen Pharma (URGN) stake by 83% in Q1 2026, buying an estimated $8.53M and bringing the position to 938,870 shares worth $16.9M. The position accounts for 0.49% of the portfolio, ranked #51.

J. Goldman & Co first reported a position in URGN in Q4 2025 and has held it in 2 quarters since. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • J. Goldman & Co held 938,870 shares of UroGen Pharma worth $16.9M as of Q1 2026.
  • J. Goldman & Co bought 425,567 UroGen Pharma shares in Q1 2026, an estimated $8.53M.
  • UroGen Pharma made up 0.49% of J. Goldman & Co's portfolio in Q1 2026, its #51 holding.
  • J. Goldman & Co first reported a position in UroGen Pharma in Q4 2025 and has held it in 2 quarters since.
  • 172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.